Pictet Asset Management Holding SA Has $30.01 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Pictet Asset Management Holding SA reduced its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 20.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 623,288 shares of the company’s stock after selling 164,232 shares during the period. Pictet Asset Management Holding SA’s holdings in Kiniksa Pharmaceuticals International were worth $30,011,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of KNSA. Amundi bought a new stake in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after acquiring an additional 1,002 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Creative Planning acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $358,000. Finally, Quantbot Technologies LP bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $43,000. 53.95% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on KNSA shares. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Finally, Wedbush upped their target price on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $62.71.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA opened at $63.95 on Wednesday. The firm has a 50-day moving average of $52.89 and a 200-day moving average of $47.30. Kiniksa Pharmaceuticals International, plc has a one year low of $26.27 and a one year high of $64.81. The company has a market cap of $4.92 billion, a PE ratio of 71.06 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period in the prior year, the firm earned $0.11 EPS. Kiniksa Pharmaceuticals International’s quarterly revenue was up 55.5% compared to the same quarter last year. Analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.25 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Ross Moat sold 1,703 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $79,513.07. Following the completion of the sale, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at $561,634.01. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. The trade was a 47.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 653,301 shares of company stock valued at $34,046,073. Insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.